Physician profile
Chaillie P Daniel
NPI 1972642312
$5,942.13
in general payments reported to CMS, 2019-2025
42 companies · $777 in 2025
The $777 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $628 · 2021: $1,019 · 2022: $803 · 2023: $1,042 · 2024: $939 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,757.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,086.54 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $779.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $469.05 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $441.00 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $412.73 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $385.02 | 2019-2021 | |
| Allergan, INC. | $289.05 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $245.08 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $226.61 | 2021-2025 | |
| Lilly USA, LLC | $178.15 | 2019-2025 | Zepbound, Mounjaro |
| Merz North America, INC. | $122.71 | 2021-2023 | Xeomin |
| Merck Sharp & Dohme LLC | $87.91 | 2019-2023 | Dificid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.34 | 2021-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.55 | 2019-2024 | Ofev |
| Phathom Pharmaceuticals, INC. | $78.62 | 2024-2025 | Voquezna |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaillie Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.